At Opticyte, we are committed to transforming the standard of care for the leading causes of organ failure, including sepsis. The problem is massive, is expensive to treat, and leads to one death every 2.8 seconds globally. Current technologies fail to provide clinicians with the definitive data they need to diagnose, monitor, and treat patients in real-time, when they have the best chance of preventing organ failure. Unlike existing oximeters, our VitalO₂ is accurate for people of all skin tones. Our VitalO₂ monitor is the first and only single solution to provide definitive, continuous, and actionable insights for these critical unmet needs. The FDA awarded Opticyte Breakthrough Device Designation on the strength of our clinical data and the promise of our technology to save lives. Opticyte's executive and advisory team includes pioneers in new optical spectroscopy and multivariate analysis technology, leaders in medical device commercialization, and medical clinicians. The company’s early funding successes, research validation, and product development milestones provide credibility and reinforce our position as a disruptive medical device innovator.